Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 193 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival December 7, 2018 ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... September 18, 2025 ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and... August 13, 2020 First Mature Estimation of Median OS for Selpercatinib in Patients with... March 12, 2025 Load more HOT NEWS We want every scientist to thrive in cancer research Breast Cancer Patient Given 2 Years to Live is Now a... No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated...
